Ultragenyx Pharmaceutical | RARE - Betriebsergebnis





Betriebsergebnis Veränderung Datum
Acadia Pharmaceuticals USD 17.39M 18.36M 2025-12
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Immunic USD -23.33M 2.67M 2025-12
Insmed USD -249.71M 11.64M 2025-12
Ionis Pharmaceuticals USD -118M 97M 2026-03
Karyopharm Therapeutics USD -17.84M 13.44M 2025-12
Kyowa Hakko Kirin JPY 38.35B 12.49B 2025-12
MacroGenics USD -12.1M 30.74M 2025-12
Moderna USD -1.39B 531M 2026-03
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
PTC Therapeutics USD -81.62M 85.11M 2025-12
Puma Biotechnology USD 22.08M 24.26M 2024-09
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
Ultragenyx Pharmaceutical USD -114M 56.89M 2025-12
Vertex Pharmaceuticals USD 1.14B 124.5M 2026-03
Xoma USD -15.64M 5.56M 2024-09